{
    "clinical_study": {
        "@rank": "26820", 
        "acronym": "PORTICO-IDE", 
        "arm_group": [
            {
                "arm_group_label": "High Risk TF Portico", 
                "arm_group_type": "Experimental", 
                "description": "Portico aortic valve via transfemoral access"
            }, 
            {
                "arm_group_label": "High Risk TF CAV", 
                "arm_group_type": "Active Comparator", 
                "description": "Commercially available transcatheter aortic valve via transfemoral access"
            }, 
            {
                "arm_group_label": "High Risk AA Portico", 
                "arm_group_type": "Experimental", 
                "description": "Portico aortic valve via alternative transcatheter access"
            }, 
            {
                "arm_group_label": "High Risk AA CAV", 
                "arm_group_type": "Active Comparator", 
                "description": "Commercially available transcatheter aortic valve"
            }, 
            {
                "arm_group_label": "Extreme Risk TF Portico", 
                "arm_group_type": "Experimental", 
                "description": "Portico aortic valve via transfemoral access"
            }, 
            {
                "arm_group_label": "Extreme Risk TF CAV", 
                "arm_group_type": "Active Comparator", 
                "description": "Commercially available transcatheter aortic valve"
            }, 
            {
                "arm_group_label": "Extreme Risk TF Registry", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with vascular access compatible with Portico only receive Portico aortic valve"
            }, 
            {
                "arm_group_label": "Extreme Risk Portico AA Registry", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with vascular access compatible with Portico only receive Portico aortic valve"
            }
        ], 
        "brief_summary": {
            "textblock": "The PORTICO clinical trial is a prospective, multi-center, randomized-controlled clinical\n      study, designed to evaluate the safety and effectiveness of the St. Jude Medical (SJM)\n      Portico Transcatheter Heart Valve and Delivery Systems (Portico) via the transfemoral and\n      transapical delivery methods, in high and extreme risk cohorts."
        }, 
        "brief_title": "Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Stenosis", 
        "condition_browse": {
            "mesh_term": "Aortic Valve Stenosis"
        }, 
        "detailed_description": {
            "textblock": "The PORTICO clinical study is limited to two subject cohorts with severe, symptomatic aortic\n      stenosis who are determined to be at high or extreme operative risk for surgical aortic\n      valve replacement. The operative risk determination of study candidates will be based on the\n      Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Risk Calculator.\n\n      The PORTICO trial will include a maximum of 1610 subjects (930 subjects in the high risk\n      [randomized] cohort, 680 subjects in the extreme risk [randomized] cohort) at up to 40\n      investigational sites.\n\n      In addition, at least one roll-in subject per investigational site for transfemoral access\n      and at least one roll-in subject per investigational site for each alternative access will\n      be enrolled into a Roll-in Registry; up to 100 subjects will be enrolled in a Valve-in-Valve\n      registry.\n\n      Study subjects will undergo clinical evaluation at Discharge, 30 days, 6 months, 1 year, and\n      annually up to 5 years after the index procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Predicted risk of operative mortality \u226515% and/or STS >8%.\n\n          -  > 21 years of age.\n\n          -  Senile degenerative aortic valve stenosis\n\n          -  Symptomatic aortic stenosis demonstrated by New York Heart Association (NYHA)\n             Functional Classification of II, III, or IV.\n\n          -  Subject or Subject's legal representative has provided written informed consent.\n\n          -  Subject and the treating physician agree that the subject will return for all\n             follow-up visits.\n\n          -  Subject's aortic annulus is 27mm diameter\n\n          -  Extreme Risk Cohort of this study must meet # 2, 3, 4, 5, 6, 7 of the above criteria,\n             and\n\n          -  Medical factors preclude operation, based on a conclusion that the probability of\n             death or serious, irreversible morbidity exceeds the probability of meaningful\n             improvement (probability of death or serious, irreversible morbidity > 50%)\n\n        Exclusion:\n\n          -  Evidence of an acute myocardial infarction within 30 days prior to index procedure\n\n          -  Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is\n             non-calcified, as verified by echocardiography.\n\n          -  Mixed aortic valve disease\n\n          -  Any percutaneous coronary or peripheral interventional procedure performed within 30\n             days prior to index procedure.\n\n          -  Pre-existing prosthetic heart valve in any valve position, prosthetic ring, severe\n             mitral annular calcification (MAC), severe mitral insufficiency.\n\n          -  Blood dyscrasias\n\n          -  History of bleeding diathesis or coagulopathy.\n\n          -  Cardiogenic shock\n\n          -  Untreated clinically significant coronary artery disease\n\n          -  Hemodynamic instability\n\n          -  Need for emergency surgery\n\n          -  Hypertrophic cardiomyopathy\n\n          -  Severe ventricular dysfunction with Left Ventricular Ejection Fraction (LVEF) <20%\n\n          -  Intracardiac mass, thrombus or vegetation.\n\n          -  Active peptic ulcer or upper GI bleeding within 3 months prior to the index\n             procedure.\n\n          -  Hypersensitivity or contraindication to aspirin, heparin, ticlopidine, or\n             clopidogrel, or sensitivity to contrast media\n\n          -  Patient has been offered surgery but has refused surgery.\n\n          -  Recent cerebrovascular accident or a transient ischemic attack\n\n          -  Renal insufficiency and/or end stage renal disease requiring chronic dialysis.\n\n          -  Life expectancy < 12 months from the time of informed consent due to non-cardiac\n             co-morbid conditions.\n\n          -  Significant aortic disease, including abdominal aortic or thoracic aneurysm; marked\n             tortuosity, aortic arch atheroma, or narrowing of the abdominal or thoracic aorta,\n             severe \"unfolding\" and tortuosity of the thoracic aorta (applicable for transfemoral\n             patients only).\n\n          -  Native aortic annulus size < 19 mm or > 27 mm\n\n          -  Aortic root angulation > 70\u00b0.\n\n          -  Currently participating in an investigational drug or device study.\n\n          -  Active bacterial endocarditis within 6 months prior to the index procedure.\n\n          -  Bulky calcified aortic valve leaflets in close proximity to coronary ostia.\n\n          -  Non-calcified aortic annulus\n\n          -  Iliofemoral vessel characteristics that would preclude safe"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "1610", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000115", 
            "org_study_id": "1203"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "High Risk TF Portico", 
                    "High Risk AA Portico", 
                    "Extreme Risk TF Portico", 
                    "Extreme Risk TF Registry", 
                    "Extreme Risk Portico AA Registry"
                ], 
                "description": "St. Jude Medical transcatheter Portico aortic valve", 
                "intervention_name": "Portico aortic valve", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "High Risk TF CAV", 
                    "High Risk AA CAV", 
                    "Extreme Risk TF CAV"
                ], 
                "description": "Commercially available transcatheter aortic valve", 
                "intervention_name": "Commercially available transcatheter aortic valve", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "jmartine13@nshs.edu", 
                "last_name": "Jeffrey Martinez"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10075"
                }, 
                "name": "Lenox Hill Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Carlos Ruiz, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Gregory Fontana, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "8", 
        "official_title": "Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO)", 
        "overall_contact": {
            "email": "cwilliams09@sjm.com", 
            "last_name": "Claire Williams"
        }, 
        "overall_official": [
            {
                "affiliation": "Cedars-Sinai Medical Center", 
                "last_name": "Raj Makkar, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Lenox Hill Hospital", 
                "last_name": "Gregory Fontana, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary Endpoint for High and Extreme Risk Cohorts: The composite endpoint of all cause mortality or disabling stroke at one year.", 
            "measure": "The composite endpoint of all cause mortality or disabling stroke at one year.", 
            "safety_issue": "Yes", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000115"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}